Key differences are observed depending on whether changes in cholesterol levels are acute or persistent during AD progression, which should take into account in the design of therapeutic approaches that enhance PINK1-parkin-mediated mitophagy for the treatment of AD. The gene discussed is PRKN; the disease is Alzheimer disease.